Gehören Sie zu den Ersten, denen das gefällt!
Making the most of the investments into developing new cancer therapies will not only increase the profits of pharma and biotech companies but will also radically alter the landscape in tackling all forms of cancer and give hope to sufferers that the disease is not the death sentence it once was.
However there are still a lot of challenges facing pharma and biotech comapnies. Running oncology trials pose different challenges to those experienced with traditional clinical development. The whole clinical process from patient recruitment through to data analysis and regulatory frameworks is challenging. This is where expertise and learning from experienced professionals makes all the difference.